New Modalities & Technologies (NMT) in Pulmonary Hypertension & Right Heart Failure Workstream

This NMT Workstream was formed in 2021 to expand the PVRI community’s awareness and understanding of emerging device technologies for treating and diagnosing PH and RHF. It comprises experienced colleagues from academia, pharma, and regulatory fields, each with expertise in drug, device, and combination development. 

Members aim to innovate and change current thinking, working in sub-groups:  

• 'Inhalation Therapies' led by Sylvia Nikkho and Sandeep Sahay
• 'Therapeutic Device Technologies' led by Marc Pritzker and John Scandurra
• 'New Therapies' led by Sudarshan Rajagopal 
• 'Imaging Technologies' led by Rahaghi Farbod, Ben Lavon and Alex Dusek
• 'Artificial Intelligence' led by Hilary DuBrock, Rahaghi Farbod and Nick Villabos
• 'Metabolic and Microbiome' led by Thenappan Thenappan
• 'Connective-tissue Disease related PH' In development 

The group meets on the first Friday of each month at 15:00 BST/GMT. If you’re interested in joining this Workstream, please get in touch.

Publications

• Rajagopal, S., Abueg, J., Hart, K. M., Lau, E., Martinez, E. C., et al. (2026) ‘Activin signaling inhibitors in pulmonary hypertension: A state-of-the-art review’. Pulmonary Circulation, 16(3), e70353
• Evolving technology for monitoring and measuring physical activity via accelerometry in patients with pulmonary hypertension – a short communication from the PVRI working group on emerging biotechnologies, Peter Fernandes, October 2021